Targeted nanomaterials for radiotherapy

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

Bibliography

• 1  Jemal A, Siegel R, Ward E et al.: Cancer statistics. CA Cancer J. Clin.57(1),43–66 (2007).
  MedlineGoogle Scholar
• 2  Mathers CD, Loncar D: Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med.3(11),e442 (2006).
  MedlineGoogle Scholar
• 3  Jain RK: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science307(5706),58–62 (2005).•• Good review describing antiangiogenic therapy-dependent ‘vascular normalization’
  Medline CASGoogle Scholar
• 4  Iyer AK, Khaled G, Fang J, Maeda H: Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today11(17–18),812–818 (2006).
  Medline CASGoogle Scholar
• 5  Duda DG, Batchelor TT, Willett CG, Jain RK: VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends Mol. Med.13(6),223–230 (2007).
  MedlineGoogle Scholar
• 6  Singh Jaggi J, Henke E, Seshan SV et al.: Selective α-particle mediated depletion of tumor vasculature with vascular normalization. PLoS ONE2,e267 (2007).• Description of actinium-225-based antiangiogenic radioimmunotherapy with evidence of vascular normalization as a means of improving delivery of subsequent chemotherapeutics.
  Google Scholar
• 7  Folkins C, Man S, Xu P et al.: Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res.67(8),3560–3564 (2007).
  Medline CASGoogle Scholar
• 8  Sengupta S, Eavarone D, Capila I et al.: Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature436(7050),568–572 (2005).• Authors present a novel ‘nanocell’ which allows a temporal release of two distinct drugs, an antiangiogenic agent along with a chemotherapeutic.
  Medline CASGoogle Scholar
• 9  Jang BS, Lim E, Hee Park S et al.: Radiolabeled high affinity peptidomimetic antagonist selectively targets α(v)β(3) receptor-positive tumor in mice. Nucl. Med. Biol.34(4),363–370 (2007).
  MedlineGoogle Scholar
• 10  Beck R, Seidl C, Pfost B et al.: (213)Bi-radioimmunotherapy defeats early-stage disseminated gastric cancer in nude mice. Cancer Sci.98(8),1215–1222 (2007).
  Medline CASGoogle Scholar
• 11  Felding-Habermann B, Lerner RA, Lillo A et al.: Combinatorial antibody libraries from cancer patients yield ligand-mimetic Arg-Gly-Asp-containing immunoglobulins that inhibit breast cancer metastasis. Proc. Natl Acad. Sci. USA101(49),17210–17215 (2004).
  MedlineGoogle Scholar
• 12  Eklund JW, Kuzel TM: Denileukin diftitox: a concise clinical review. Expert Rev. Anticancer Ther.5(1),33–38 (2005).
  MedlineGoogle Scholar
• 13  Dearling JL, Pedley RB: Technological advances in radioimmunotherapy. Clin. Oncol. (R. Coll. Radiol.)19(6),457–469 (2007).
  MedlineGoogle Scholar
• 14  McDevitt MR, Ma D, Lai LT et al.: Tumor therapy with targeted atomic nanogenerators. Science294(5546),1537–1540 (2001).•• Landmark paper describing effective cancer radioimmunotherapy with the potent α-particle emitter actinium-225
  Medline CASGoogle Scholar
• 15  McDevitt MR, Barendswaard E, Ma D et al.: An α-particle emitting antibody ([213Bi] J591) for radioimmunotherapy of prostate cancer. Cancer Res.60(21),6095–6100 (2000).
  Medline CASGoogle Scholar
• 16  Jurcic JG, Larson SM, Sgouros G et al.: Targeted α-particle immunotherapy for myeloid leukemia. Blood100(4),1233–1239 (2002).
  Medline CASGoogle Scholar
• 17  Mulford DA, Jurcic JG: Antibody-based treatment of acute myeloid leukaemia. Expert Opin. Biol. Ther.4(1),95–105 (2004).
  MedlineGoogle Scholar
• 18  Li Y, Tian Z, Rizvi SM, Bander NH, Allen BJ: In vitro and preclinical targeted α-therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen. Prostate Cancer Prostatic Dis.5(1),36–46 (2002).
  Medline CASGoogle Scholar
• 19  Larson SM, Nelp WB: Radiopharmacology of a simplifield technetium-99m-colloid preparation for photoscanning. J. Nucl. Med.7(11),817–826 (1966).
  MedlineGoogle Scholar
• 20  Kam NW, O'Connell M, Wisdom JA, Dai H: Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction. Proc. Natl Acad. Sci. USA102(33),11600–11605 (2005).
  Medline CASGoogle Scholar
• 21  DeNardo SJ, DeNardo GL, Natarajan A et al.: Thermal dosimetry predictive of efficacy of 111In-ChL6 nanoparticle AMF-induced thermoablative therapy for human breast cancer in mice. J. Nucl. Med.48(3),437–444 (2007).• Targeted alternating magnetic field-induced thermoablative cancer therapy
  Medline CASGoogle Scholar
• 22  Maier-Hauff K, Rothe R, Scholz R et al.: Intracranial thermotherapy using magnetic nanoparticles combined with external beam radiotherapy: results of a feasibility study on patients with glioblastoma multiforme. J. Neurooncol.81(1),53–60 (2007).
  Medline CASGoogle Scholar
• 23  Lapotko DO, Lukianova E, Oraevsky AA: Selective laser nano-thermolysis of human leukemia cells with microbubbles generated around clusters of gold nanoparticles. Lasers Surg. Med.38(6),631–642 (2006).
  MedlineGoogle Scholar
• 24  Toth E, Bolskar RD, Borel A et al.: Water-soluble gadofullerenes: toward high-relaxivity, pH-responsive MRI contrast agents. J. Am. Chem. Soc.127(2),799–805 (2005).
  Medline CASGoogle Scholar
• 25  Zakharian TY, Seryshev A, Sitharaman B et al.: A fullerene-paclitaxel chemotherapeutic: synthesis, characterization, and study of biological activity in tissue culture. J. Am. Chem. Soc.127(36),12508–12509 (2005).
  Medline CASGoogle Scholar
• 26  Ashcroft JM, Tsyboulski DA, Hartman KB et al.: Fullerene (C60) immunoconjugates: interaction of water-soluble C60 derivatives with the murine anti-gp240 melanoma antibody. Chem. Commun. (Camb.)28,3004–3006 (2006).
  MedlineGoogle Scholar
• 27  Sayes CM, Marchione AA, Reed KL, Warheit DB: Comparative pulmonary toxicity assessments of C60 water suspensions in rats: few differences in fullerene toxicity in vivo in contrast to in vitro profiles. Nano Lett.7(8),2399–2406 (2007).
  Medline CASGoogle Scholar
• 28  Cagle DW, Kennel SJ, Mirzadeh S, Alford JM, Wilson LJ: In vivo studies of fullerene-based materials using endohedral metallofullerene radiotracers. Proc. Natl Acad. Sci. USA96(9),5182–7 (1999).• One of the early papers describing in vivo biodistribution of water-soluble fullerenes.
  Medline CASGoogle Scholar
• 29  Liu Z, Cai W, He L et al.: In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat. Nano2(1),47–52 (2007).•• Best example of noncovalent carbon nanotube (CNT) modification for in vivo tumor targeting.
  Medline CASGoogle Scholar
• 30  Li Z, Hulderman T, Salmen R et al.: Cardiovascular effects of pulmonary exposure to single-wall carbon nanotubes. Environ. Health Perspect.115(3),377–382 (2007).
  Medline CASGoogle Scholar
• 31  Zhang LW, Zeng L, Barron AR, Monteiro-Riviere NA: Biological interactions of functionalized single-wall carbon nanotubes in human epidermal keratinocytes. Int. J. Toxicol.26(2),103–113 (2007).
  Medline CASGoogle Scholar
• 32  Raja PM, Connolley J, Ganesan GP et al.: Impact of carbon nanotube exposure, dosage and aggregation on smooth muscle cells. Toxicol. Lett.169(1),51–63 (2007).
  Medline CASGoogle Scholar
• 33  Singh R, Pantarotto D, Lacerda L et al.: Tissue biodistribution and blood clearance rates of intravenously administered carbon nanotube radiotracers. Proc. Natl Acad. Sci. USA103(9),3357–3362 (2006).• One of first papers describing in vivo handling of water-soluble CNTs.
  Medline CASGoogle Scholar
• 34  McDevitt MR, Chattopadhyay D, Kappel BJ et al.: Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. J. Nucl. Med.48(7),1180–1189 (2007).•• Covalent modification of CNTs to achieve specific tumor targeting in vivo.
  Medline CASGoogle Scholar
• 35  Guo J, Zhang X, Li Q, Li W: Biodistribution of functionalized multiwall carbon nanotubes in mice. Nucl. Med. Biol.34(5),579–583 (2007).
  Medline CASGoogle Scholar
• 36  McDevitt MR, Chattopadhyay D, Jaggi JS et al.: PET imaging of soluble yttrium-86-labeled carbon nanotubes in mice. PLoS ONE (2007) (In Press).
  Google Scholar
• 37  Khan MK, Nigavekar SS, Minc LD et al.: In vivo biodistribution of dendrimers and dendrimer nanocomposites – implications for cancer imaging and therapy. Technol. Cancer Res. Treat.4(6),603–613 (2005).
  Medline CASGoogle Scholar
• 38  Esfand R, Tomalia DA: Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discov. Today6(8),427–436 (2001).
  Medline CASGoogle Scholar
• 39  Patri AK, Kukowska-Latallo JF, Baker JR Jr: Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv. Drug Deliv. Rev.57(15),2203–2214 (2005).
  Medline CASGoogle Scholar
• 40  Duncan R, Izzo L: Dendrimer biocompatibility and toxicity. Adv. Drug Deliv. Rev.57(15),2215–2237 (2005).
  Medline CASGoogle Scholar
• 41  Malik N, Wiwattanapatapee R, Klopsch R et al.: Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo.J. Control. Release65(1–2),133–148 (2000).
  Medline CASGoogle Scholar
• 42  Lesniak WG, Kariapper MS, Nair BM et al.: Synthesis and characterization of PAMAM dendrimer-based multifunctional nanodevices for targeting αvβ3 integrins. Bioconjug. Chem.18(4),1148–1154 (2007).
  Medline CASGoogle Scholar
• 43  Backer MV, Gaynutdinov TI, Patel V et al.: Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol. Cancer Ther.4(9),1423–1429 (2005).
  MedlineGoogle Scholar
• 44  Hong S, Leroueil PR, Majoros IJ et al.: The binding avidity of a nanoparticle-based multivalent targeted drug delivery platform. Chem. Biol.14(1),107–115 (2007).• Description of the advantages that nanoparticle multivalency might provide as drug-delivery systems.
  Medline CASGoogle Scholar
• 45  Koyama Y, Talanov VS, Bernardo M et al.: A dendrimer-based nanosized contrast agent dual-labeled for magnetic resonance and optical fluorescence imaging to localize the sentinel lymph node in mice. J. Magn Reson. Imaging25(4),866–871 (2007).•• Describes the synthesis and application of a versatile dendrimer-based magnetic resonance (MR)/near-infrared (NIR) optical imaging agent for the detection of sentinel lymph node.
  MedlineGoogle Scholar
• 46  Shukla R, Thomas TP, Peters JL et al.: HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb. Bioconjug. Chem.17(5),1109–1115 (2006).•• Specific targeting of HER2-expressing tumors with anti-HER2-mAb conjugated dendrimer.
  Medline CASGoogle Scholar
• 47  Patri AK, Myc A, Beals J et al.: Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjug. Chem.15(6),1174–1181 (2004).• Example of antibody-conjugated dendrimer constructs.
  Medline CASGoogle Scholar
• 48  Okuda T, Kawakami S, Akimoto N et al.: PEGylated lysine dendrimers for tumor-selective targeting after intravenous injection in tumor-bearing mice. J. Control. Release116(3),330–336 (2006).
  Medline CASGoogle Scholar
• 49  Kobayashi H, Kawamoto S, Bernardo M et al.: Delivery of gadolinium-labeled nanoparticles to the sentinel lymph node: comparison of the sentinel node visualization and estimations of intra-nodal gadolinium concentration by the magnetic resonance imaging. J. Control. Release111(3),343–51 (2006).• Describes dendrimer-based MR imaging agents and a generation-dependent improvement on lymphatic system visualization.
  Medline CASGoogle Scholar
• 50  Le UM, Cui Z: Long-circulating gadolinium-encapsulated liposomes for potential application in tumor neutron capture therapy. Int. J. Pharm.312(1–2),105–112 (2006).
  Medline CASGoogle Scholar
• 51  Barth RF, Coderre JA, Vicente MG, Blue TE: Boron neutron capture therapy of cancer: current status and future prospects. Clin. Cancer Res.11(11),3987–4002 (2005).
  Medline CASGoogle Scholar
• 52  Gupta B, Torchilin VP: Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice. Cancer Immunol. Immunother.56(8),1215–1223 (2007).
  Medline CASGoogle Scholar
• 53  Sofou S, Thomas JL, Lin HY et al.: Engineered liposomes for potential α-particle therapy of metastatic cancer. J. Nucl. Med.45(2),253–260 (2004).
  Medline CASGoogle Scholar
• 54  Cuenca AG, Jiang H, Hochwald SN et al.: Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer107(3),459–466 (2006).
  Medline CASGoogle Scholar
• 55  Jin C, Wu H, Liu J, Bai L, Guo G: The effect of paclitaxel-loaded nanoparticles with radiation on hypoxic MCF-7 cells. J. Clin. Pharm. Ther.32(1),41–47 (2007).
  MedlineGoogle Scholar
• 56  Duncan R: Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer6(9),688–701 (2006).• Good review of polymer conjugates currently used clinically as well as those that hold promise for future clinical use.
  Medline CASGoogle Scholar
• 57  Jaggi JS, Seshan SV, McDevitt MR et al.: Mitigation of radiation nephropathy after internal α-particle irradiation of kidneys. Int. J. Radiat. Oncol. Biol. Phys.64(5),1503–1512 (2006).
  MedlineGoogle Scholar
• 58  Rolleman EJ, Forrer F, Bernard B et al.: Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [(177)Lu-DOTA (0), Tyr(3)] octreotate. Eur. J. Nucl. Med. Mol. Imaging34(5),763–771 (2007).
  MedlineGoogle Scholar